LivsMed Q1 2026 Revenue Up 5.5% YoY, Net Loss Improves, Cash Holdings at 16.4B KRW

Consolidated Q1 2026 revenue: 10.26B KRW (up 5.5% YoY from 9.73B)
Consolidated operating loss: 8.37B KRW (widened from 6.29B, due to increased R&D)
Consolidated net loss: 5.88B KRW (improved from 6.29B loss)
Cash holdings: 16.44B KRW; debt ratio 3.8% (stable financial position)
R&D expenditure: 3.63B KRW (35% of revenue); total IP rights: 983
Signed supply agreement with HealthTrust (US GPO) covering ~1,800 hospitals
Patent litigation ongoing but invalidation ruled in favor; financial impact expected limited
Post-report: acquired 2.05% stake in LAD (unlisted foreign company) for 1.45B KRW